HDAC11: A novel target for improved cancer therapy

Biomed Pharmacother. 2023 Oct:166:115418. doi: 10.1016/j.biopha.2023.115418.

Yan Liu ¹, Xuechao Tong ², Weina Hu ³, Da Chen ⁴

Affiliations

1 First Department of Oncology, the Fourth Affiliated Hospital of China Medical University, Shenyang 110032, Liaoning, China.
2 Department of Emergency, the Fourth Affiliated Hospital of China Medical University, Shenyang 110032, Liaoning, China.
3 Department of General Practice, The Fourth Affiliated Hospital of China Medical University, Shenyang 110032, Liaoning, China. Electronic address: [email protected].
4 Department of Emergency, the Fourth Affiliated Hospital of China Medical University, Shenyang 110032, Liaoning, China. Electronic address: [email protected].

PMID: 37659201 DOI: 10.1016/j.biopha.2023.115418

Abstract

Histone deacetylase 11 (HDAC11) is a unique member of the histone deacetylase family that plays an important role in the regulation of gene expression and protein function. In recent years, research on the role of HDAC11 in tumors has attracted increasing attention. This review summarizes the current knowledge on the subcellular localization, structure, expression, and functions of HDAC11 in tumors, as well as the regulatory mechanisms involved in its network, including ncRNA and substrates. Moreover, we focus on the progress made in targeting HDAC11 to overcome tumor therapy resistance, and the development of HDAC11 inhibitors for Cancer treatment. Collectively, this review provides comprehensive insights into the potential clinical implications of HDAC11 for Cancer therapy.

Keywords

Acetylation; Cancer; Drug resistance; Function; HDAC11 inhibitors; Histone deacetylase 11; Regulatory mechanisms.

Name
Email *

	Sorry, but the email address you supplied was invalid.